Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
C-C motif chemokine ligand 28 (CCL28) is a member of the CC chemokine family, primarily expressed by epithelial cells in mucosal tissues such as the gut, lung, salivary glands, and breast. CCL28 acts as a chemoattractant for T and B lymphocytes expressing the CCR10 receptor and for eosinophils via CCR3, thereby orchestrating the mucosal recruitment and homing of immune cells. Aside from its chemotactic role, CCL28 has been shown to possess broad-spectrum antimicrobial activity against certain bacteria and fungi. It is constitutively present in mucosal secretions but can be upregulated in inflammation or infection, marking its importance in both innate and adaptive immunity. CCL28 is of growing interest as both a disease biomarker (notably in breast cancer) and a potential therapeutic target in infection, immune-related, and inflammatory conditions[1][2][3][4].
Chemokine receptor modulation (drugs could modulate interaction with CCR10/CCR3, but none are currently approved) Immunomodulation (potential approach under investigation)[2]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on C-C motif chemokine ligand 28 (CCL28).